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Abstract:  Bovine  leukemia  virus  (BLV)  is  a  retrovirus  closely  related  to  the  human  
T-lymphotropic virus type 1 (HTLV-1). BLV is a major animal health problem worldwide 
causing  important  economic  losses.  A  series  of  attempts  were  developed  to  reduce 
prevalence, chiefly by eradication of infected cattle, segregation of BLV-free animals and 
vaccination. Although having been instrumental in regions such as the EU, these strategies 
were unsuccessful elsewhere mainly due to economic costs, management restrictions and 
lack  of  an  efficient  vaccine.  This  review,  which  summarizes  the  different  attempts 
previously  developed  to  decrease  seroprevalence  of  BLV,  may  be  informative  for 
management of HTLV-1 infection. We also propose a new approach based on competitive 
infection with virus deletants aiming at reducing proviral loads. 
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1. Introduction 
As early as in the 19th century, a series of reports already described the occurrence of clinical signs 
associated  with  enzootic  bovine  leukosis  (EBL).  Initial  observations  from  Leisering  of  yellowish 
nodules in the enlarged spleen of a leukocytic cow were communicated in the German literature in 
1871  ([1],  cited  by  [2]).  Three  years  later,  Bollinger  described bovine leukemia  as  a  well-defined 
clinical  entity,  and  in  1876  Siedamgrotzky  and  Hofmeister  recorded  the  first  cases  of  bovine 
lymphocytic malignancies ([3,4]; cited by [2]). Thus, Europe, and more specifically the Memel area, 
then regarded as East Prussia and now located in the contemporary Lithuania, might be thought of as 
the cradle of enzootic bovine leukemia ([5]; cited by [6]). Diffusion and wide spread of the disease 
occurred by the introduction of European cattle breeds in countries free of the disease. Despite all these 
pieces of evidence, the infectious nature of EBL etiological agent was discovered many decades later 
based on epidemiological evidence [7]. Finally, the causative  agent of  this malignant disease  was 
isolated in culture in 1969 [8] and designated bovine leukemia virus (BLV).  
BLV  is  an  oncogenic  B-lymphocytotropic  retrovirus  that  infects  cattle  inducing  a  persistent 
infection with diverse outcomes [9–16]. The great majority of BLV-infected animals (around 70%) are 
asymptomatic carriers of the virus. In these animals, neither clinical symptoms nor alteration of the 
total lymphocyte count are evidenced. Thus, they can only be identified by the presence of anti-BLV 
antibodies  and/or  of  proviral  DNA  [14,16].  Approximately,  one-third  of  BLV-infected  bovines 
develop a benign polyclonal proliferation of B cells called persistent lymphocytosis (PL). This clinical 
condition is characterized by an increase in the absolute number of peripheral blood circulating B 
lymphocytes associated  with an inversion of the B/T lymphocyte ratio [9,14,17,18]. Despite these 
hematologic alterations, PL animals do not develop any other apparent clinical signs. PL is usually 
stable for several years but can also progress to the tumor phase [9,14,18]. 
The most conspicuous clinical manifestation of BLV infection is the development of lymphoid 
tumors.  Fatal  lymphoma  or  lymphosarcoma  (LS)  occurs  in  less  than  5–10%  of  infected  animals, 
predominantly  adult  cattle  older  than  4–5  years  old  [10,14].  The  development  of  tumors  is  not 
necessarily preceded by a phase of PL, but this is the case in two-thirds of the animals [14,19]. Unlike 
persistent lymphocytosis, B-cell expansion is of mono- or oligo-clonal origin [13,14,20–24]. Local 
proliferation of B cells, called lymphosarcoma, can occur within different organs and tissues leading to 
a  series  of  defects  that  are  finally  incompatible  with  the  survival  of  the  animal.  In  addition, 
transformed B cells can also induce the enlargement of lymph nodes and cause lymphoma [10,14]. 
Besides an impact on survival, BLV infection also impairs the immune system leading to opportunistic 
infections [25–27].  
2. Transmission  
BLV is transmitted horizontally, essentially through the transfer of infected cells [28]. Since free 
virus is very unstable, BLV-infected cells (B-lymphocytes, monocytes/macrophages, etc.) present in Viruses 2011, 3                         
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blood or milk appear to be the best vehicles of natural transmission [16]. Due to the high number of 
infected cells they contain, animals with PL are particularly efficient in transmitting the virus [28]. In 
herds, iatrogenic procedures largely account for the propagation of the infection. Cattle management 
procedures which involve transfer of infected blood (i.e., dehorning, ear tattooing, rectal palpation, 
and, essentially, the use of infected needles) were postulated as a common mode of transmission [29]. 
In addition, prolonged direct contact between infected and healthy animals has also been considered as 
a risk factor for BLV transmission. Transfer of infected blood might also occur in regions with high 
density  of  hematophagous  insects  [30,31].  Perinatal  or  postnatal  transmission  of  BLV  frequently 
happens in herd conditions. The rate of transmission in utero varies between 4 and 18% [32–34], with 
highest risk in calves born from cows with PL [35]. Although BLV transmission has been postulated to 
occur  from  cow  to  calves  via  milk,  this  route  of  infection  was  only  demonstrated  experimentally  
[36–38]. Despite the presence of BLV proviral DNA in colostrum and milk from infected cows, calves 
can remain uninfected over extended periods of time likely due to the protective role of maternal 
antibodies present in the colostrum [39–41]. 
3. Epidemiology 
Sero-epidemiological surveys have shown that BLV infection is widespread in all continents except 
in  Europe.  Efforts  in  the  implementation  of  control  measures  and  campaigns  to  eradicate  BLV 
infection  in  Western  Europe  have  been  successful  [42–45].  Recently,  the  European  Economic 
Community  (EEC)  declared  most  of  its  member  states  as  officially  free  of  EBL.  In  contrast,  the 
situation is different in Eastern Europe where the disease is still present in several countries (Bulgaria, 
Croatia, Estonia, Latvia, Poland, Romania, Ukraine) [46]. 
Similar attempts to eradicate BLV infection in Australia and New Zealand dairy herds began in the 
mid-1990s. More than 98% of dairy herds were negative in 2005 [47,48].  
Detailed  information  about  the  epidemiological  situation  in  the  United  States  of  America  was 
collected through the National Animal Health Monitoring (NAHMS). Survey studies in 2007 revealed 
that 83.9% of U.S. dairy herds were positive for BLV [49]. Recent epidemiological data is available 
for several provinces in Canada. All agree in indicating high seroprevalence rates reaching up to 89% 
and 20.8%–37.4% at herd and individual levels, respectively [50–54].  
In  South  America,  individual  infection  rates  between  34  and  50%  were  reported  in  Colombia, 
Venezuela, Chile and Uruguay [55–58]. In Argentina, individual and herd prevalence levels scale up to 
32.8%  and  84%,  respectively  [59].  In  Brazil,  the  individual  prevalence  of  BLV  infection  varies 
considerably among states and reaches levels beyond 50% [60–67]. 
The  epidemiological  situation  in  Asia  is  more  uncertain.  The  International  Organization  of 
Epizootics (OIE)  recognizes that BLV is present in  Indonesia, Taipei (China) and Mongolia [46]. 
Surprisingly, only about 5% of animals were positive for BLV in Cambodia and Taiwan [68,69]. The 
seroprevalence rates in Japan were found to be 28.6% and 68.1% at the individual and herd levels, 
respectively [70]. In Korea, individual seroprevalence rates exceeded 50% whilst 86.8% of dairy herds 
were infected [71]. 
Regarding  the  Middle  East  countries,  reports  indicate  that  the  prevalence  of  BLV  infection  is 
somewhat lower than in other regions of the world, i.e., about 20% [27,72–74]. Exceptions in this Viruses 2011, 3                         
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region  include  Turkey  and  Iran  where  the  herd  seroprevalence  levels  climb  to  48.3%  and  64.7%, 
respectively, while the individual seroprevalence in Iran was estimated between 17 and 24.6% [75–77], 
although some argue that prevalence levels are lower [78]. 
4. Preventive and Therapeutic Strategies  
Understanding the mechanisms of pathogenesis has been instrumental for developing therapeutic 
and preventive strategies against BLV infection. The different approaches that were developed are 
reviewed in this section. 
4.1. Removal or Segregation Approaches 
4.1.1. Test and Eliminate 
A  first  strategy  is  to  identify  and  eliminate  BLV-infected  cattle.  This  approach  requires 
identification  of  BLV-positive  animals  either  by  hematological,  genomic  or  serological  methods, 
immediate removal of positive cases from the herd and, finally, prompt slaughtering [7,79,80].  
This  “test  and  elimination”  methodology  has  been  instrumental  in  accomplishing  the  BLV-free 
status at herd and regional scales within a relatively brief period of time when compared to other 
alternatives [7,43–45,81–89]. Evidence of the efficiency of this strategy is illustrated by the successful 
eradication of the disease in several countries of Western Europe.  
Although this approach has been efficient, its feasibility faces some important restrictions. A key 
limitation  is  that  the  initial  prevalence  rate  of  infection  should  not  be  high  due  to  its  very  high 
economic cost. Hence, this strategy can be particularly justified in pedigree breeds having high genetic 
potential as well as for export to BLV-free countries. Nevertheless, even when the rates of infection 
are low, the “test and eliminate” approach is a burdensome strategy due to diagnostics, premature 
culling and replacement of reactors. Loss of genetic and reproductive potential must also be considered. 
In fact, this strategy requires governmental economic compensation policies to be successful. If no 
official subsidizing action is adopted by the local authorities, the costs of implementation of such a 
strategy quickly exceeds the potential benefits. Countries such as USA, Canada, Argentina, and Japan 
lacking financial compensatory policies usually failed to obtain adherence to enroll in these programs 
[49–54,59,70,90,91].  
To summarize, the pros and cons of the “test and eliminate” strategy are outlined in Table 1.  
4.1.2. Test and Segregate 
Another approach aims at reducing part of these costs by segregating instead of culling infected 
animals.  Control  programs  based  on  segregation  require  detection  of  seropositive  animals  and 
confinement of BLV-infected and seronegative herds in strictly separated areas [28,92,93]. It has been 
proposed that a minimum distance of 200 meters must separate the two herds to avoid transmission 
[92]. An alternative option is to keep the animals in the same farm and to manage them separately. For 
optimal  results  with  any  of  these  options,  separate  equipment  or  at  least  careful  disinfection  and 
hygiene of non-disposable equipment should be implemented (Table 1). The main advantage of this 
approach is the reduction of costly losses due to compulsory premature culling and replacement of Viruses 2011, 3                         
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BLV-positive animals. Although quite demanding, this type of program has been useful to decrease 
prevalence or even achieve eradication of the disease [84,92,94]. The disadvantage is that there is a 
permanent risk of reintroducing infected animals and, therefore, it may be slower than the ‘test and 
eliminate’ option [95]. 
Table 1. Currently available approaches for bovine leukemia virus (BLV) control and prevention.  
APPROACH  BASIS OF THE 
CONTROL PROGRAM  ADVANTAGES  DISADVANTAGES 
TEST AND 
ELIMINATE 
Identify BLV-infected 
cattle and slaughter 
positive reactors 
Efficient   May become cost-prohibitive and 
impracticable depending on the 
initial prevalence levels  
Requires only minimal 
investment on facilities  Needs constant surveillance 
Requires official compensatory 
policies to be successful 
BLV-free status might 
be achieved in a 
relatively short period 
TEST AND 
SEGREGATE 
Detect and isolate  
BLV-infected cattle in 
separate herds  
Does not need 
replacement of culled 
BLV-infected cattle  
Needs structural and operational 
accommodation of infected and 
non-infected cattle in strictly 
separated areas 
Manage separately 
infected and non-infected 
cattle in the same housing 
facilities  
Increases costs due to duplicated 
housing facilities and equipment 
Requires permanent surveillance 
Needs long-term commitment to 
the program  
TEST AND 
MANAGE 
Take biosafety and 
management measures to 
minimize exposure of 
animals to the infectious 
agent 
Cost-effective  
Intensively laborious 
Requires strict adherence to the 
rigorous implemented measures 
Requires only minimal 
investment on facilities  Needs long-term commitment to 
the program  
Does not need 
replacement of culled 
BLV-infected cattle 
Susceptible to human and 
environmental factors 
Needs adequate training of 
personnel 
 
The  removal/segregation  approaches  both  require  specific  and  regular  identification  of  infected 
animals.  Discrimination  of  BLV-infected  animals  from  the  herd  was  originally  performed  by 
hematologic screening based on leukocyte counts [7]. Later on, more sensitive and specific techniques 
(i.e., AGID, agar gel-immunodiffusion test and ELISA, enzyme-linked immunosorbent assay) became 
routine diagnostic methods. These serologic assays performed on serum or milk were widely used and 
became  the  official  tests  recommended  for  international  trade  [96].  However,  these  tests  can  be 
misleading since the presence of anti-BLV antibodies does not necessarily imply that the animals are 
infected and vice versa. Indeed, there is a “latency” period of several weeks between infection and Viruses 2011, 3                         
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seroconversion [97]. Also, calves can have anti-BLV antibodies due to maternal antibodies from the 
colostrum [33,36,39,98,99] or to parturition [99]. A significant fraction of these calves will remain 
uninfected although they carry anti-BLV antibodies. 
Therefore, a more accurate way to monitor BLV infection is PCR [100,101]. BLV-infected cattle 
can further be classified according to their proviral load (PVL) [102]. In fact, the proviral load in the 
peripheral blood is a predictive marker of transmission risk. Thus, PVL can be used as a criterion to 
discriminate  and  eliminate/segregate  highly  infected  cows  [102–104].  Besides  technical  challenges 
(contaminations), the disadvantages of PCR-based diagnostics are higher costs and the need of more 
complex equipment.  
4.2. Corrective Management and Veterinary Practices 
This  type  of  approach  aims  at  limiting  transfer  of  BLV-infected  cells  present  in  blood,  milk, 
secretions, excretions, syringes or surgical instruments.  
Among  the  diverse  control  measures  that  can  be  implemented  in  a  preventive  or  corrective 
management control plan, the following constitute essential practices:  
-  (i) use of individual, single-use needles and syringes during vaccination or therapeutic protocols; 
-  (ii)  use  of  individual,  single-use  obstetrical  sleeves  (or  at  least  replacement  between 
examination of BLV-reactors and non-infected animals);  
-  (iii) use of disposable equipment (or at least cleaning, disinfection or sterilization of reusable 
materials  and  surgical  instruments)  in  procedures  such  as  dehorning,  tattooing,  implanting, 
cauterizing, castration or ear-tagging;  
-  (iv) use of electrical or gas burning devices rather than gouging equipment during dehorning;  
-  (v)  feeding  calves  with  colostrum  or  whole  milk  from  non-infected  dams,  pasteurized 
colostrum from BLV-infected cows or milk replacer;  
-  (vi)  elimination  of  insects,  particularly  in  densely  populated  farm  areas  (milking  areas,  
free-stalls,  barns)  in  order  to  minimize  potential  transmission  between  animals  through 
arthropod vectors;  
-  (vii) natural and/or artificial insemination and embryo transfer with BLV-free dams and bulls.  
Other potentially beneficial management control measures might include: (i) prevent introduction of 
infected animals into the herd by testing and quarantining/isolating newcomers; (ii) separate animals 
by  age to decrease  contacts (iii) minimize movement of  animals between milking/feeding  groups;  
(iv) use individual calf hutches for newborn calves; and (v) limit access to outside visitors.  
Compared to the test and eliminate/segregate strategies, the “corrective management and veterinary 
practices” approach is clearly more cost-effective. Neither investments on facilities nor removal of 
infected cattle nor constant surveillance of the herd serological status are required. The disadvantages 
of the corrective management approach are that practices are intensively laborious and vulnerable to 
environmental and human variables. In this regard, careful appraisal of the effort required before the 
enrolment into a corrective management control plan must be considered. Strict compliance to the 
rigorous measures should be enforced and a long-term engagement with the program is required until 
fruitful benefits of this strategy are observed (see Table 1). In addition, adequate training of personnel Viruses 2011, 3                         
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and farm employees on BLV prevention and biosecure practices might be considered. The efficacy of 
a  “corrective  management  and  veterinary  practices”  strategy  based  exclusively  on  strict  sanitary 
measures is still controversial [104–106].  
4.3. Selection of BLV-Resistant Cattle  
Livestock breeding programs exploit selection of genetic traits beneficial for production (e.g., milk 
yield, growth, reproduction) [107,108]. In principle, it would be possible to select breeds that are less 
susceptible or even resistant to BLV infection. Immune responsiveness  and heritable resistance  or 
susceptibility  to  infection  are  influenced  by  the  host  major  histocompatibilty  complex  (MHC)  
[107–110]. The Bovine Lymphocyte Antigen (BoLA) refers to the major histocompatibilty complex in 
bovine species (Bos taurus and Bos indicus) [111–113]. Pioneering work suggested that host genetics 
factors  determined  cattle  susceptibility  to  BLV  infection  [114].  Early  studies  initially  attributed  a 
linkage  between  resistance  or  susceptibility  of  cattle  to  development  of  subclinical  PL  and 
serologically defined class I BoLA-A alleles [115]. However, frequencies of BoLA-A alleles diverge 
considerably between breeds [116–119] and the association was not confirmed at the population level 
[117]. More sensitive analyses showed that the development of PL was apparently more closely related 
to  class  II  DRB2  genes  [120].  Further  characterization  of  genes  within  the  class  II  BoLA  locus 
evidenced  that  the  strongest  association  with  resistance  or  susceptibility  to  PL  corresponded  to 
polymorphisms of the class II DRB3 gene [121,122], the only one actively transcribed among the three 
DRB genes [123]. Reduced proviral loads were observed in animals carrying the resistance-associated 
DRB3.2*11  allele,  conferring  biological  significance  to  this  association  [124].  These  observations 
were later confirmed and extended to other breeds [125,126]. More recently, a strong linkage between 
the allele DRB3.2*0902 and genetic resistance to PL was demonstrated in Holstein cows [127]. The 
presence of DRB3.2*0902 allele correlates with a low proviral load profile (LPL). It was proposed that 
cattle harboring the *0902 allele and presenting this LPL profile might be unable to transmit BLV in 
herd conditions [102]. Polymorphisms in the BoLA-DRB3 genes were also correlated with resistance 
and susceptibility to leukemia/lymphoma in cows [116,126,128,129]. In the experimental sheep model, 
gene  polymorphisms  of  ovine  leukocyte  antigen  (OLA)-DRB1  can  predict  the  frequency  of  tumor 
development [130]. 
Besides  the  polymorphic  BoLA-DRB3  gene,  other  non-MHC  genes  are  also  considered  to  be 
involved in the development or progression of BLV infection. An association between TNF-alpha and 
BLV  pathogenesis  has  been  established  in  ovine  [131]  and  bovine  species  [132].  In  the  latter,  a 
polymorphism  in  the  promoter  region  of  the  TNF-α  gene  (allele  -824G)  might  contribute  to  PL 
susceptibility [132]. Furthermore, polymorphisms in alpha-albumin genes might also be associated 
with resistance to BLV infection [133]. 
Selection of BLV resistant animals based on genetic traits faces a series of limitations. First, the 
relevance and statistical significance of the identified markers must be analyzed at the population level. 
Large-scale studies in different breeds are required to assess the efficiency and the consequences of 
selection based on these markers.  It is likely that identification of other BoLA polymorphisms or 
resistance genes will be required to achieve robust and efficient selection. Genetic resistance to BLV 
infection appears to be a complex mechanism under the control of multiple genes, each contributing Viruses 2011, 3                         
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slightly  to  the  phenotype  [110,134,135].  Poor  correspondence  between  the  specific  alleles  and 
development of PL or LS [103,122,127] clearly indicates that other viral or host genetic, epigenetic 
and/or environmental factors contribute to the outcome of infection [136,137]. In this scenario, it might 
become  difficult  to  prioritize  one  allele  over  other/s  as  an  absolute  genetic  selection  marker  for 
selecting BLV resistant cattle [103].  
A second limitation is that selection of BLV-resistant animals encounters a major risk due to the 
narrowing  of  the  genetic  pool  of  the  cattle  population.  This  loss  of  biodiversity  is  particularly 
important in resistance to other pathogens [137,138]. On the other hand, selection for BLV resistance 
may also have adverse effects on beneficial productivity traits. In this sense, it should be mentioned 
that humoral immune response to other economically important viral diseases (i.e., foot and mouth 
disease,  bovine  herpesvirus  type  1  and  bovine  viral  diarrhea  virus)  was  not  adversely  affected  in 
bovines carrying the DRB3.2*0902 allele [139]. Perhaps a more important problem is that selection 
based on disease resistance might also have adverse effects on productivity traits [134,138].  
Due to these limitations, the benefits of selection programs for BLV resistance might not reach a 
positive benefit:cost ratio.  
4.4. Epigenetic Modulation of Viral Expression as Therapy  
This type of approach issued from fundamental research on viral dynamics in BLV-infected sheep. 
Conceptually, the host-pathogen interplay during infection is characterized by a very dynamic kinetics 
resulting  in  a  subtle  equilibrium  between  the  virus,  which  attempts  to  replicate,  and  the  immune 
response, which seeks to exert tight control of the pathogen. This equilibrium appeared to be tightly 
regulated by epigenetic mechanisms. In particular, the extent of chromatin condensation is an essential 
epigenetic control mechanism determining gene expression and is partly dependent on the level of 
histone acetylation. In a certainly oversimplified model, chromatin relaxation results from acetylation 
of  the  conserved  N-terminal  histone  tails  that  reduces  the  interaction  with  the  negatively  charged 
phosphate backbone. This allows unwinding of DNA, leading to gene expression by favoring access of 
transcriptional activators to their target sites. Conversely, gene silencing or transcriptional repression is 
the  consequence  of  preventing  access  of  transcriptional  activators  due  to  DNA  packaging  into 
condensed  chromatin.  This  is  mediated  by  acetyl  removal  of  lysine  residues  from  histone  
N-terminal  tails,  restoring  a  positive  charge  and  increasing  the  affinity  of  histones  for  DNA.  
The degree of acetylation of the core histones reflects an intrinsic balance between the activities of  
two  families  of  functionally  antagonistic  enzymes:  histone  deacetylases  (HDACs)  and  histone 
acetyltransferases  (HATs),  which  withdraw  or  incorporate  acetyl  groups  into  core  histones, 
respectively [140–146].  
In BLV infected cells, the virus is stably integrated apparently in a transcriptionally silent state 
[147–154].  Two  epigenetic  mechanisms,  histone  acetylation  and  DNA  hypermethylation,  correlate 
with BLV transcriptional repression [149,155–160]. The lack of viral expression in a large proportion 
of infected cells prevents efficient clearance of the virus by the immune system despite the presence of 
a vigorous immune response. The rationale of a potential therapy consists in inducing viral expression 
in  provirus-carrying  cells,  thereby  exposing  infected  cells  to  the  host  immune  response.  A  key 
observation for this working model was that increasing the BLV promoter efficiency paradoxically Viruses 2011, 3                         
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decreases proviral loads [161]. In this context, a therapeutic approach based on the modulation of host 
epigenetic  mechanisms  was  proposed  to  treat  BLV  infection  and  disease  [159,162,163].  Different 
HDAC  inhibitors  (valproate  VPA,  trichostatin  A  TSA,  trapoxin  TPX)  efficiently  enhance  viral 
transcription directed by the BLV promoter in vitro [155,159]. HDAC inhibitors also increase viral 
expression during ex vivo short-term culture of peripheral blood mononuclear cells (PBMCs) from 
BLV-infected  sheep  and  cattle  [155,159].  Consistent  with  its  inhibitory  activity,  VPA  induces 
hyperacetylation of histone H3 [164]. VPA treatment, in the absence of any other cytotoxic drug, 
induced tumor regression in BLV-infected sheep and was efficient for leukemia/lymphoma therapy in 
the  sheep  model.  However,  VPA  treatment  was  inefficient  in  preventing  primary  infection  and 
reducing PVL in asymptomatic sheep [159].  
The efficacy of VPA in BLV-infected cows is presently unknown. However, large scale treatment 
of  BLV  infected  herds  with  HDAC  inhibitors  such  as  VPA  is  not  justified  mainly  due  to  costs. 
Nevertheless, a treatment with VPA, alone or possibly in combination with antiretroviral drugs (AZT) 
may still be useful to treat animals with high genetic value.  
This  strategy  might  also  hold  promise  for  treating  adult  T  cell  leukemia  (ATL)  or  human  
T-lymphotropic  virus-associated  myelopathy/tropical  spastic  paraparesis  (HAM/TSP),  diseases  for 
which no satisfactory treatment currently exists (see Section 5) [165,166]. It is noteworthy that VPA 
alone  had  no  effect  in  simian  T  lymphotropic  virus  type  1  (STLV-1)  infected  monkeys  but 
significantly reduced the PVL when combined with AZT [167].  
4.5. Vaccination  
During the last few decades, a series of attempts were performed to develop a vaccine against BLV 
[11,16,168–170].  
4.5.1. Inactivated Virus Vaccines  
Early studies evaluated preparations of inactivated BLV obtained from persistently infected cell 
lines (fetal lamb kidney or FLK, LK15, Bat2Cl1 cell lines) [171–175]. Inactivation was obtained by 
treatment of the virus with different chemical agents (N-acetylethylenimine, 0.1% Triton X-100, 0.1% 
formalin, formaldehyde, aminomethylated compounds). These inactivated virus vaccines induced a 
strong specific neutralizing humoral response and partially protected sheep and cattle from low dose 
viral  challenge  [171,172,175].  Protection  roughly  correlated  with  the  efficiency  of  the  vaccine  to 
induce a strong neutralizing humoral response. However, vaccinated animals became infected with 
high challenge doses.  
4.5.2. Cell-Derived Vaccines  
Several tentative vaccines were based on cell lysates from:  
-  plasma membranes or cell extracts from BLV tumors [176,177]. 
-  BLV-infected FLK or SF-28 cells fixed with 3% glutaraldehyde [178].  
-  ovine virus non-producing NP2 cells synthesizing only the env gene products (gp51 and gp30) 
and the capsid protein (p24) of BLV [179,180].  Viruses 2011, 3                         
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Although  some  of  these  trials  led  to  partial  protection,  this  strategy  has  the  intrinsic  risk  of 
transmitting infection. Therefore, viral subunits were tested for prophylactic immunization. 
4.5.3. Viral Subunit Vaccines 
First subunit vaccines were designed with the gp51 surface envelope glycoprotein [178,181–184]. 
The gp51 sequence is indeed well conserved among BLV isolates [91,185–196] and carries at least 
three neutralizing epitopes [185,197–203].  
A  subunit  vaccine  including  purified  gp51  obtained  from  culture  supernatant  of  FLK  cells 
inactivated with 0.01% N-acetylethylenimine was immunogenic but did not consistently protect from 
BLV  challenge  [178].  Native  viral  gp51  glycoprotein  obtained  from  FLK  cell  culture  supernatant 
absorbed in Al(OH)3 also failed to prevent BLV infection in calves [182]. A similar unsuccessful 
attempt was undertaken with the p24 protein [178].  
Based  on  the  ability  of  anti-BLV  antibodies  in  the  colostrum  to  prevent  infection,  the  three 
aforementioned  conventional  approaches  were  focused  on  inducing  an  optimal  humoral  response 
[33,39,41,98,99,204–207]. Further experimental evidence supporting the role of the humoral response 
was obtained by successful immunization of naïve sheep with immunoglobulin G from BLV-infected 
sheep [208]. It should be emphasized that these early vaccination trials included only few animals and 
were performed over short periods of time. More importantly, the main concern of these experiments 
was to determine the correct challenge dose encountered under real herd conditions. On the other hand, 
a major problem of these vaccines was the fast decline of protective antibody titers. Therefore, the 
significance of these vaccination strategies in herd conditions remains questionable.  
Although important, the humoral response quickly appeared to be insufficient for achieving full 
protection  against  BLV  infection  [209–211].  Additionally,  antibody  titers  showed  fast  decline  in 
vaccinated  animals,  an  undesired  feature  in  an  effective  vaccine.  Due  to  these  initial  failures  in 
vaccination against BLV, more emphasis was given on the cellular component of the immune response.  
4.5.4. Recombinant Vaccinia Virus 
Recombinant vaccinia virus (RVV) was used as a vehicle for immunization against BLV antigens. 
RVV  is  a  live  recombinant  vector  having  a  broad  host  range  specificity,  the  capacity  to  carry  a  
large  amount  of  genetic  information  and,  most importantly,  the  ability  to  elicit  both  humoral  and  
cell-mediated immunity. 
Preliminary  studies  with  RVV  coding  for  gp51  alone  induced  neither  a  humoral  response  nor 
protected against BLV in sheep or rabbits [209,212]. In contrast, RVV harboring the complete env 
gene (RVV-env) which encodes both gp51 and gp30 glycoproteins produced a neutralizing humoral 
response in rabbits and sheep [209,210,212–216]. In one study, RVV-env failed to induce detectable 
neutralizing specific antibodies and conferred only partial protection in naïve sheep after challenge 
with BLV [214]. However, the BLV proviral loads were decreased in vaccinated sheep. An efficient 
immune response correlated with type 1 helper T cell proliferation and delayed hypersensitivity with 
predominant involvement of CD8 cytotoxic T lymphocytes [214,215,217]. In two other studies, similar 
RVV-env vaccines induced a strong humoral and CD4+ T cell response and protected against BLV 
challenge [209,210]. Unfortunately, the RVV-env vaccines were inefficient in cows [211,216–218]. Viruses 2011, 3                         
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Remarkably, vaccination with RVV-env in cattle resulted in increasing titers of IgG1 antibodies which 
might indicate a type 2 response [218,219]. A RVV vector expressing the gag, pol and env genes also 
failed to protect cattle after challenge [218].  
4.5.5. Synthetic Peptides 
Short  peptides  mimicking  gp51  B-  and  T-cell  epitopes  were  tested  as  potential  immunogens 
[210,220]. Preliminary analyses with peptides encapsulated in mannan-coated liposomes as delivery 
system  induced  significant  humoral  response  and  specific  Th1  type  immunity  in  mice  and  sheep 
models [221–223]. A different cocktail that included multiple synthetic  peptides of Th, Tc  and  B 
epitopes failed to induce protection after challenge despite a cell mediated immune response. In the 
short  term,  the  peptide  vaccine  partially  reduced  BLV  replication  [184].  Finally,  a  peptide 
encompassing  a  minimal  9-mer  CTL  epitope  of  gp51  mixed  with  Freund’s  adjuvant  induced  a  
cell-mediated response but did not protect most vaccinated sheep against infection [224,225]. 
Synthetic  peptide-based  vaccines  showed  poor  performance  possibly  due  to  inadequate 
stereochemical structure and partial epitope presentation.  
4.5.6. DNA Vaccines  
DNA vaccines can induce a long-lasting immunity engaging both humoral and cellular components 
of the immune responses.  
A DNA vaccine containing the env gene under the control of the cytomegalovirus promoter did not 
induce a vigorous antibody response but stimulated cellular mediated immunity in vaccinated calves. 
Partial protection was achieved after BLV challenge [226].  
Another  DNA  vaccine  was  designed  to  express  the  Tax  transactivator  protein.  The  Tax  vector 
suppressed BLV replication in immunized sheep likely through a Th1-cell response involving CTL 
activity [227,228]. However, a more recent study showed that a Tax DNA vaccine elicited a cytotoxic 
response in the early phase of infection but did not prevent later infection [229]. Neither Tax-specific 
cytotoxic responses nor the proviral loads were predictive of disease outcome.  
As other previously developed immunogens, DNA vaccines were thus disappointing.  
4.6. Competitive Infection by Attenuated Proviruses 
Failure  of  “traditional  vaccines”  was  likely  due  to  inadequate  or  short-lived  stimulation  of  all 
immunity components. Ideally, the optimal vaccine would therefore contain a large number of viral 
factors permanently stimulating the immune response. Attenuated derivatives of BLV proviruses meet 
these requirements [169,170,230–237]. 
Replication-competent BLV proviruses lacking accessory genes and cis-acting LTR sequences were 
designed and evaluated in rats and rabbits [230,231]. A first generation of these genetically simpler 
viruses was constructed by co-injection of independent vectors encoding gag-pol and env genes. These 
constructs were devoid of tax, rex, R3 and G4 and contained promoter cis-acting regulatory sequences 
of spleen necrosis virus (SNV). These BLV simpler hybrid derivatives were infectious and induced 
specific antibodies in a rat model [230,231]. A second type of virus contained gag, pol and env genes Viruses 2011, 3                         
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in a single genome under the control of SNV regulatory sequences. This viral vector was competent for 
replication and induced antibody responses against gag and env structural proteins in rats and rabbits 
[231,232,235]. While PVL were decreased, the viral vector induced protection against viral challenge 
in a rabbit model.  
Another approach to design attenuated BLV viruses was to delete genes dispensable for infectivity 
but required for efficient replication [169]. Using an infectious molecular clone [150], a series of BLV 
mutant  or  deletant  proviruses  were  engineered  and  evaluated  for  infectivity,  replication  and 
pathogenicity  in  sheep.  As  predicted,  large  deletions  in  the  structural  genes  (gag,  pol,  and  env) 
abrogated  infectivity  [169,238].  Other  specific  mutations  within  the  genome  (the  capsid  major 
homology  region,  the  catalytic  sites  of  the  integrase)  were  deleterious  [169,170].  A  mutation 
(nucleotide  coordinate  6073)  of  the  immunoreceptor  tyrosine-based  activation  (ITAM)  motifs 
localized in the cytoplasmic tail of the transmembrane gp30 glycoprotein impaired replication but not 
infectivity.  Importantly,  the  pathogenic  potential  of  the  6073-mutated  provirus  was  significantly 
reduced but the anti-viral humoral response was preserved [170,233,234,237,239].  
Other attenuated BLV proviruses were obtained by deletion of the region expanding from the end of 
the env gene to the splice acceptor site of the tax/rex mRNA [169]. These mutants lacking R3 and G4 
sequences  were  infectious  but  replicated  at  extremely  low  levels  [240].  Similar  conclusions  were 
drawn from HTLV mutant proviruses deleted in the ORFs encoding the p12
I and p13
II/p30
II orthologs 
of R3 and G4 [241–243]. The BLV R3+G4 deletant (pBLVDX) elicited a wild type humoral response 
but was only very rarely pathogenic in sheep, with a single exception among 20 sheep observed after 
an unusually long period of latency (7 years) [237].  
To summarize, two types of BLV mutants (pBLV6073 and pBLVDX) were infectious, replicated at 
low  levels  but  elicited  a  wild-type  like  immune  response.  Importantly,  these  attenuated  viruses 
conferred long-term protection after challenge with a wild-type strain in sheep and partly in cattle 
[233,234]. Indeed, the idea is that these deleted viruses persistently infect cows and interfere with 
wild-type BLV propagation in herds. The number of BLV-positive cells is also expected to be reduced 
in the milk of vaccinated cows, impairing the efficiency of BLV transmission to calves. However, 
calves born from vaccinated cows with these attenuated mutants would be protected through passive 
immunization. Whether the attenuated strain is transmitted from cow to calf is presently unknown.  
Since  attenuated  viruses  can  sometimes  be  pathogenic,  an  important  issue  of  these  vaccines  is 
biosafety. Pathogenicity can be reduced by combining multiple mutations and deletions that do not 
affect  infectivity  but  reduce  replication.  Another  risk  is  conversion  of  the  attenuated  vaccine  to  
wild-type. Conceptually, this conversion would only be possible by recombination with another BLV 
strain.  Since  the  very  large  majority  of  the  cattle  are  infected  in  endemic  areas  (see  Section  3. 
Epidemiology),  the  risk  is  that  a  fraction  of  vaccinated  animals  would  become  infected  with  a  
wild-type virus, a process that occurs anyway with high frequencies. It should also be emphasized that 
virus  recombinations  were  not  observed  with  attenuated  strains  even  under  enforced  conditions 
[233,234]. 
Trials are currently ongoing to evaluate efficacy and safety of this competitive infection strategy in 
real herd conditions. Viruses 2011, 3                         
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5. BLV as a Model for HTLV Therapy and Prevention 
BLV  and  HTLV-1  are  closely  related  deltaretroviruses  sharing  a  similar  genomic  organization 
[14,244–246].  Although  HTLV  and  BLV  infect  different  target  cells  (T  and  B  lymphocytes, 
respectively) and induce distinct hematological disorders, the two viruses persist, spread and transform 
through similar mechanisms. A shared feature of their replication strategy is transcriptional silencing, a 
process  that  allows  escape  from  the  host  immune  response  [147,150,152,153,247].  Both  viruses 
replicate  by  colonizing  new  lymphocytes  (infectious  cycle)  as  well  as  by  mitosis  of  the  host  cell 
(clonal  expansion)  [248–250].  A  major  driving  force  of  viral  spread  is  delivered  by  the  Tax 
oncoprotein that continuously stimulates proliferation of the infected cell [246,251,252].  
In a perspective of comparative virology, the BLV system is a model of pathogenesis for HTLV 
[170,253–257] (see Table 2). Important outcomes are outlined in this section.  
Table 2. Present and future prevention and treatment strategies for BLV and HTLV-1. 
  BOVINE LEUKEMIA VIRUS 
(BLV) 
HUMAN T-CELL LEUKEMIA VIRUS 
(HTLV-1) 
  PREVENTIVE MEASURES 
Avoid or minimize 
viral transmission 
through infected- 
cells present in 
blood, secretions or 
excretions  
- Use disposable material and 
individual single-use of needles and 
syringes  
- Clean, disinfect or sterilize non-
disposable reusable materials, 
equipment and surgical instruments 
during dehorning, tattooing, 
implanting, cauterizing, castration or 
ear-tagging procedures 
- Refrain from sharing needles or syringes 
with anyone  
- Avoid donating blood, tissues or organs 
Avoid or minimize 
viral transmission 
through sexual 
contact 
-  Consider natural and/or artificial 
insemination and embryo transfer 
with BLV-free donors 
- Take precautions to prevent sexual 
transmission  
Avoid or minimize 
viral transmission 
through infected-
cells present in milk  
- Feed calves with colostrum or whole 
milk from non-infected dams 
- Use milk replacer or pasteurized 
colostrum  
- Refrain from breast-feeding  
- Consider short-term breastfeeding (less than 
6 months) 
- Inactivate virus by heating or freeze/thaw 
procedures 
  VACCINATION 
  Not available  Not available 
  SELECTION 
  Not efficient  Not applicable 
  COMPETITIVE INFECTION 
  Currently tested  Not applicable 
  TREATMENT 
  VPA but not cost-efficient  AZT+IFN in acute ATL 
 
 
AZT+IFN+VPA  in  acute  ATL  and 
lymphoma?  
AZT+VPA in HAM/TSP? 
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5.1. Prevention  
In the absence of an effective vaccine, control of HTLV-1 infection relies on prevention practices 
aiming to reduce viral transmission [258].  
5.1.1. Interruption or Short-Term Breast-Feeding  
Vertical transmission via postnatal breast-feeding is considered as the most clinically relevant route 
for HTLV-1 transmission, particularly when practiced over long periods [259–262]. Cell-associated 
but not free virus in breast milk appears to be the source of infection [263,264]. Consistently, the main 
preventive measure to decrease the risk of mother to child transmission would be to avoid breast 
feeding. However, this measure is not always easy to adopt due to behavioral, social and societal 
reasons. For example, refraining from breast-feeding can lead to social stigma or discrimination and 
explain  why  women  might  have  difficulties  to  follow  this  recommendation.  Furthermore,  when 
sanitary conditions are not met, it might be hazardous to use reconstituted milk with contaminated 
water. Malnutrition being a primary cause of infant death, poverty can also hamper the use of artificial 
milk.  Finally,  there  is  no  optimal  substitute  for  natural  milk  that  provides  passive  immunity,  as 
described  earlier  for  BLV.  Therefore,  whilst  avoiding  or  limiting  breast-feeding  is  an  effective 
preventive measure in developed countries where safer alternatives exist, it is frequently not adequate 
for other regions.  
Other strategies also used for BLV include:  
-  limit the duration of breast feeding (to less than 6 months) [265–267].  
-  inactivate the virus by heating or freezing-thawing [268–270]. 
Besides milk, pre- and perinatal infection with HTLV-1 occurs less frequently through transfer of 
cord  blood  and  placenta  syncytiotrofoblastic  cells  [261,271].  When  the  PVLs  are  high,  HTLV-1 
transmission could be impaired with anti-retroviral drugs such as AZT.  
5.1.2. Prevention of Sexual Transmission 
Sexual intercourse is another route of HTLV-1 transmission that occurs more efficiently from men 
to women [272–275]. As for HIV, the use of condoms is the optimal measure preventing HTLV-1 
transmission [258].  
5.1.3. Prevention of Iatrogenic Transmission  
Although less frequent, iatrogenic transmission of HTLV-1 occurs with low efficacy due to needle 
sharing by intravenous drug users [276–278]. In fact, HTLV-2 appears to be more prevalent in this 
group [279–282]. Therefore, individuals are strongly recommended to refrain from sharing needles or 
syringes [258,283]. Iatrogenic transmission of HTLV-1 also occurs in organ transplanted recipients 
and long-term hemodialyzed patients [284–289].  
Parenteral  infection  by  transfusion  of  contaminated  blood  is  a  potential  threat  for  HTLV-1 
transmission. Rates of 5–6% infection were found among blood donors of highly endemic areas, such 
as the Caribbean Islands and Japan [290–292]. In medium prevalence areas of South America, these Viruses 2011, 3                         
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rates  are  close  to  2%  [293–299].  Systematic  screening  for  HTLV-1  in  blood  banks  has  become 
compulsory in many countries. Rapid implementation measures were adopted in highly endemic areas 
like Japan (1986), Brazil (1993), the Caribbean and the French Isles (1989), as well as in many other 
developed countries despite low seroprevalence rates (France, USA, Canada, Australia, Netherlands or 
Denmark). Later on, blood bank screening was applied in developing countries with medium to high 
seroprevalence  among  blood  donors  (Argentina:  2004,  Peru:  1999).  This  policy  proved  to  be 
successful  to  decrease  HTLV-1  spread  by  blood  transfusion  [300–304].  Unfortunately,  official 
screening programs still lack in other regions with high prevalence (Middle East) [305,306], further 
reflecting differences between industrialized and developing countries.  
5.2. Vaccination Strategies  
Vaccination is probably the best strategy against HTLV-1 infection particularly in endemic areas 
with high prevalence and in developing economies where other control measures are not implemented 
[307]. Unfortunately, an efficient, safe and cost-effective vaccine is not available.  
As for BLV, an efficient HTLV-1 vaccine should elicit both humoral response and cell-mediated 
immunity [308]. Focus was also given to the envelope glycoproteins (gp46 and gp21) and the Tax 
transactivator. Attempts included: 
-  heat-inactivated HTLV-1 [309]; 
-  env glycoproteins produced in Escherichia coli [310]; 
-  DNA vaccines encoding tax or env genes (in combination with RVV-env or RVV-env+gag) 
[311,312];  
-  synthetic peptide derived from env gp46 [309,313,314] and Tax [315–319];  
-  complex chimeric synthetic multivalent peptide vaccines [320–323];  
-  recombinant vaccinia viruses expressing gag and/or env proteins [312,324–329].  
Despite interesting preliminary data, none of these vaccines achieved final development mainly due 
to partial or short-lived response, safety concerns and perhaps also a lack of interest from an industrial 
partner. No matter the reasons, a vaccine for HTLV or BLV is currently unavailable and will clearly 
require significant further development. 
5.3. Epigenetic Modulation Strategy and Gene Activation Therapy 
In the absence of satisfactory therapy and based on preclinical trials performed in animal models 
[159,167], gene activation therapy is an option to improve treatment of HTLV-infected patients. As 
previously  described  for  BLV  (see  Section  3.4),  this  approach  is  designed  to  activate  viral  gene 
expression with VPA in order to expose virus-positive cells to the host immune response [159,256].  
In primary cells freshly isolated from HAM/TSP patients, VPA induced hyperacetylation, triggered 
viral  expression  and  was  proapoptotic  [159,162,163].  Despite  early  fluctuations,  the  PVLs  were 
however not significantly affected after two years of VPA treatment [166]. Importantly, VPA did not 
alter the anti-viral CTL response and generated only minor side effects. Long term treatment with VPA 
is thus safe but does not alleviate the condition of HAM/TSP. Further attempts to improve treatment 
are ongoing. Among these, the combination of VPA and AZT can reduce PVL in STLV-1 infected  Viruses 2011, 3                         
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P. papio [167]. If applicable to humans, this treatment could be rapidly translated into clinical therapy 
and reduce the risk of developing HAM/TSP.  
For ATLL, the standard treatment is currently a combination of AZT and alpha-interferon. This 
regimen  is  partly  efficient  for  the  acute  form  but  unfortunately  inoperant  for  lymphoma  ATLL 
[330,331].  Very  recently,  an  exciting  perspective  has  been  presented  at  the  15th  International 
Conference on Human Retrovirology: VPA combined with AZT and PEG-alpha-interferon induced 
complete response in 33% of patients associated with molecular remissions (i.e., drop of PVL below 
threshold levels) [165]. 
The epigenetic therapy initially developed in the BLV model may thus provide novel opportunities 
for HTLV-induced diseases.  
6. Conclusion  
In this review, we outlined the currently available approaches to decrease infection rates of BLV: test 
and  eliminate,  segregate  or  manage  (see  Table  1).  Treatment  of  BLV  leukemia  with  VPA  is  not 
economically sustainable except  for  animals with high  genetic value.  In the  absence of  an  efficient 
vaccine, a new strategy based on competitive infection with deletant viruses is presently being evaluated.  
Although aims and ethical rules are different for HTLV and BLV, there is an interesting parallelism 
in prevention and therapeutic measures (see Table 2). An effective vaccine against these viruses is still 
desperately lacking. Both systems have benefited from each other leading to a better understanding of 
the mechanisms of viral persistence and pathogenesis.  
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